Growth Hormone Therapy – At What Age Is It Effective

Growth hormone therapy (GHT) is most effective when started in children between ages 2 and 16, before the growth plates in the bones permanently close. In adults, GHT can still provide meaningful metabolic benefits, but height gains are no longer possible after epiphyseal fusion (the point when bone growth plates seal shut, typically by age 18 in females and age 21 in males).

The Age Window That Determines Everything

Children diagnosed with growth hormone deficiency (GHD) before age 13 show the most dramatic height increases from treatment. GHD is a medical condition where the pituitary gland, a pea-sized gland at the base of the brain that controls hormone production, fails to secrete enough somatotropin (the scientific name for human growth hormone) to support normal development.

The earlier treatment begins, the more growth potential remains available. A child who starts therapy at age 4 with 3 to 4 additional growth-plate-open years ahead will typically gain significantly more final adult height than one who begins at age 13.

Key Finding: Studies published in peer-reviewed endocrinology journals show that children starting GHT at younger than age 8 gain an average of 4 to 6 centimeters more in final adult height compared to those who begin treatment after age 12.

How Bone Age Differs From Chronological Age

A child’s bone age (the biological maturity of the skeleton, measured via an X-ray of the left hand and wrist) often differs from their actual birthday age. This distinction is critical for treatment decisions.

A 10-year-old with a bone age of 8 has more remaining growth potential than a 10-year-old with a bone age of 12. Physicians at pediatric endocrinology centers across the United States, including institutions like Boston Children’s Hospital, Cincinnati Children’s Hospital, and Children’s Hospital Los Angeles, routinely assess bone age before prescribing GHT.

Bone age assessment uses a standardized reference system called the Greulich and Pyle Atlas, a radiographic atlas developed from hand and wrist X-rays of American children that allows radiologists to match a patient’s skeletal maturity to a population reference. Some centers also use the Tanner-Whitehouse method, a scoring system that evaluates individual bones in the hand separately before combining scores into a final bone age estimate.

The gap between bone age and chronological age meaningfully shifts treatment urgency. A 12-year-old with a bone age of 9 may still have 4 to 5 years of effective GHT ahead. A 12-year-old with a bone age of 14 may have fewer than 12 months before plates close permanently, making immediate initiation critical.

Specific FDA-Approved Age Ranges for Different Diagnoses

The U.S. Food and Drug Administration (FDA) has approved recombinant human growth hormone, meaning lab-synthesized GH that mirrors the body’s own hormone, for several distinct conditions, each with its own age-related criteria.

1. Growth hormone deficiency in children: Approved from infancy onward, with treatment typically initiated between ages 2 and 13.
2. Turner syndrome (a chromosomal condition affecting females that causes short stature): FDA-approved starting as young as age 2.
3. Prader-Willi syndrome (a genetic disorder causing low muscle tone and stunted growth): Approved starting at age 2, sometimes earlier in specialized clinical settings.
4. Small for gestational age (SGA) children who fail to catch up: Approval generally begins at age 2 if catch-up growth has not occurred by then.
5. Idiopathic short stature (ISS), meaning short stature with no identifiable medical cause: FDA-approved for children whose predicted adult height falls below 5 feet 3 inches for males and 4 feet 11 inches for females.
6. Chronic kidney disease: Approved for pediatric patients before transplant.
7. Short stature homeobox-containing gene (SHOX) deficiency, a genetic condition causing disproportionate short stature: FDA-approved for children, typically identified between ages 3 and 12.
8. Noonan syndrome, a genetic disorder that can impair growth: FDA-approved for pediatric patients, with treatment commonly initiated between ages 4 and 13.
9. Adult GHD: Approved without a strict upper age cutoff, though response diminishes with advancing age.

Each of these indications carries a distinct dosing protocol and monitoring schedule. Physicians do not use identical dosing across diagnoses even when patients are the same age, because underlying physiology differs substantially between, for example, a child with Turner syndrome and one with isolated pituitary GHD.

What Happens When Treatment Starts During Puberty

Starting GHT during puberty, roughly ages 10 to 16 for most American children, presents a narrowing but still meaningful treatment window. Puberty accelerates bone maturation rapidly, which simultaneously accelerates growth plate closure.

Physicians frequently use GnRH agonists (medications that temporarily delay puberty by suppressing gonadotropin-releasing hormone, the chemical signal that triggers sexual development) alongside GHT in certain patients. This combination can extend the effective treatment window by 1 to 2 years in carefully selected cases, allowing more growth to occur before plates seal.

The most commonly used GnRH agonists in the United States include leuprolide acetate (sold under the brand name Lupron Depot) and histrelin acetate (sold as Supprelin LA). Both work by continuously stimulating GnRH receptors until they become desensitized, effectively switching off the puberty signal from the brain.

Clinical Note: The Lawson Wilkins Pediatric Endocrine Society, a U.S.-based professional organization that sets standards for pediatric hormone treatment, recommends reassessing GHT annually during puberty to determine whether continued treatment remains beneficial given remaining bone-plate openness.

The decision to combine GnRH agonists with GHT is not made lightly. These medications carry their own side effect profiles, including temporary bone density reduction and emotional changes during the suppression period, and they are not appropriate for all patients. A specialist at a pediatric endocrinology clinic will weigh the projected height gain against the risks and the individual child’s psychological readiness for delayed puberty.

Adult GHT: Realistic Expectations Past the Growth Window

Adults retain meaningful benefits from GHT even after height gains become impossible. Growth hormone in adults primarily regulates body composition (the ratio of fat to lean muscle mass), bone density, lipid metabolism (how the body processes fats and cholesterol), and cardiac function.

Adults diagnosed with GHD through confirmed pituitary gland testing, specifically the insulin tolerance test (ITT) or glucagon stimulation test, can qualify for insurance-covered GHT in the United States regardless of age.

Adult GHD is classified into two distinct subtypes that affect treatment decisions differently. Childhood-onset GHD refers to patients who were deficient as children and whose deficiency persists into adulthood. Adult-onset GHD refers to patients who develop GHD later in life, most commonly from pituitary tumors called pituitary adenomas, surgical damage to the pituitary, radiation therapy to the brain, or traumatic brain injury (TBI). Both subtypes qualify for treatment under FDA-approved guidelines, but their baseline IGF-1 levels and dosing requirements often differ.

Research from Johns Hopkins University and the Mayo Clinic confirms that adults with untreated GHD show accelerated cardiovascular risk, including elevated LDL cholesterol, reduced cardiac muscle mass, and higher rates of metabolic syndrome (a cluster of conditions including high blood pressure, excess abdominal fat, and abnormal blood sugar that increases heart disease risk). GHT significantly reverses several of these markers within 6 to 12 months of starting treatment.

The Cost Reality Across Age Groups

Growth hormone therapy is one of the most expensive long-term treatments in American medicine. Cost varies based on diagnosis, dosing weight, and insurance coverage.

• Pediatric GHT typically costs between $10,000 and $60,000 per year without insurance.
• Adult GHT often runs $1,000 to $5,000 per month out of pocket for those without coverage.
• Medicare and most private insurance plans cover GHT when documented GHD is proven through stimulation testing.
• The Novo Nordisk, Pfizer, Eli Lilly, and Genentech patient assistance programs offer cost-reduction pathways for qualifying low-income families in the United States.

Insurance approval rates are meaningfully higher for children with confirmed GHD than for adults seeking GHT for age-related decline, since the FDA has not approved GHT as an anti-aging treatment.

Several branded GH products are currently available in the United States, and their prices vary. Major brands include Norditropin (Novo Nordisk), Genotropin (Pfizer), Humatrope (Eli Lilly), Saizen (EMD Serono), and Omnitrope (Sandoz). Omnitrope is the only biosimilar growth hormone product currently approved by the FDA for use in the United States, and it typically costs 20% to 30% less than branded equivalents, making it an increasingly common choice for cost-sensitive families.

A newer long-acting GH formulation called somatrogon (brand name Ngenla, developed by Pfizer and OPKO Health) received FDA approval in 2023 and requires only once-weekly injection rather than daily dosing. This advancement is particularly meaningful for pediatric patients and families struggling with daily injection compliance, and its price point is expected to be comparable to existing branded daily options.

Diagnosing GHD: The Tests That Gate Treatment Access

Access to GHT at any age requires passing through a diagnostic process that confirms genuine hormone deficiency rather than normal variation in stature or body composition.

For children, the standard diagnostic pathway includes:

• IGF-1 blood test: Measures insulin-like growth factor 1, a protein produced by the liver in response to growth hormone, serving as a proxy marker for overall GH activity.
• IGFBP-3 blood test: Measures insulin-like growth factor binding protein 3, a carrier protein that travels with IGF-1 in the bloodstream and provides additional diagnostic precision, particularly useful in very young children where IGF-1 levels are naturally low.
• GH stimulation test: Involves administering a chemical trigger such as arginine, clonidine, or glucagon and measuring how much GH the pituitary releases in response; a peak response below 10 nanograms per milliliter typically confirms deficiency in children.
• MRI of the pituitary gland: Rules out structural causes such as tumors or congenital abnormalities.
• Bone age X-ray: Establishes remaining growth window.
• Karyotype testing: Ordered for females to rule out Turner syndrome, which requires its own distinct treatment approach.

For adults, the peak GH cutoff on stimulation testing is more stringent, generally set below 3 to 5 nanograms per milliliter, depending on the laboratory and test method used.

A critical and often overlooked diagnostic variable is body mass index (BMI). Obesity significantly suppresses GH secretion in stimulation testing, causing falsely low peak GH values in people who do not have true GHD. Endocrinologists at major U.S. academic medical centers use BMI-adjusted cutoff values to avoid misdiagnosing obese patients as GH deficient when their suppressed levels actually reflect normal physiology altered by excess adipose tissue (body fat).

Two stimulation tests are typically required to confirm GHD in adults, because a single abnormal result carries a false-positive rate high enough to make dual testing the standard of care under Endocrine Society guidelines. In children, two tests are also often performed, though a single test may suffice when a clear structural cause such as a pituitary tumor or congenital pituitary hypoplasia (underdevelopment of the pituitary gland) is already confirmed on MRI.

Neonatal and Infant GHT: The Earliest Possible Intervention

Congenital GHD (GHD present from birth) can cause neonatal hypoglycemia (dangerously low blood sugar in newborns), micropenis in male infants, and prolonged neonatal jaundice. These signs often trigger early pituitary evaluation, and some infants are diagnosed and treated within the first weeks or months of life.

The Pediatric Endocrine Society acknowledges that GHT in the neonatal period is primarily aimed at correcting metabolic instability rather than height outcomes at that stage. However, early treatment prevents developmental complications and establishes a therapeutic foundation that supports normal growth trajectory from the earliest possible point.

Diagnosis in newborns frequently requires a GH random level test rather than a stimulation test, because newborns naturally have higher basal GH levels than older children, making stimulation tests less interpretively reliable in this age group. An undetectable or very low random GH in a symptomatic newborn is considered strong evidence of congenital GHD.

Long-Term Monitoring and When Therapy Transitions or Stops

Pediatric patients who reach their final adult height after growth plates close face a critical decision point called transition, the period between pediatric and adult endocrinology care, typically occurring between ages 18 and 25.

During transition, approximately 25% to 40% of patients who needed GHT as children will no longer qualify for adult GHT because their pituitary function normalizes after puberty completes. Re-testing is required at transition.

Those who do qualify for continuation benefit remarkably from sustained therapy. Research from the KIMS database (the Pfizer International Metabolic Database, one of the largest real-world longitudinal datasets tracking adult GHT outcomes) demonstrates that adults maintaining GHT for 10 or more years show sustained improvements in cholesterol profiles, bone mineral density, and self-reported quality of life scores.

Important Fact: The American Association of Clinical Endocrinologists (AACE) and the Endocrine Society, both U.S.-based organizations that publish clinical practice guidelines, recommend re-testing all pediatric GHD patients at transition before continuing adult GHT, rather than assuming ongoing deficiency automatically.

The transition period is also when patients frequently experience gaps in care, a practical problem well documented in U.S. pediatric endocrinology literature. Pediatric endocrinologists stop seeing patients at age 18 to 21, while adult endocrinologists may be unfamiliar with the nuances of childhood-onset GHD. Advocacy groups including the Human Growth Foundation, a nonprofit organization that supports patients with growth disorders across the United States, actively work to educate both patients and adult providers about smooth transition protocols.

A small but important subset of patients experience recurrent GHD later in adult life after a period of normal pituitary function post-transition. These individuals require repeat stimulation testing if symptoms of GHD such as fatigue, central weight gain, reduced bone density, or worsening cholesterol panels re-emerge in their 30s, 40s, or beyond.

Variables That Shift the Effective Age Range

Several clinical and biological factors directly alter whether GHT will be effective at a given age:

• Midparental height (the average of both parents’ heights, used to predict a child’s genetic height potential): Low midparental height reduces expected GHT response.
• Compliance with daily injections: GHT is administered via subcutaneous injection (a shot delivered just under the skin), typically every day or 6 days per week; missed doses significantly reduce outcomes at any age.
• Nutritional status: Protein-calorie malnutrition blunts GH receptor sensitivity at every age.
• Thyroid function: Undiagnosed hypothyroidism (underactive thyroid gland) can mask or mimic GHD and must be corrected before GHT begins.
• Onset of puberty timing: Early puberty shortens the pediatric treatment window; delayed puberty extends it.
• GH receptor sensitivity: A small percentage of patients carry mutations in the GH receptor gene (associated with Laron syndrome, a rare genetic condition where the body cannot respond to GH despite normal or elevated GH production), making standard GHT ineffective regardless of age or dose.
• Cortisol and thyroid replacement status: Patients with panhypopituitarism (a condition where the pituitary fails to produce multiple hormones simultaneously) must have cortisol and thyroid deficiencies corrected first, because untreated cortisol deficiency makes GHT both less effective and potentially dangerous.
• Psychosocial stress and sleep quality: Chronic psychological stress and poor sleep independently suppress GH secretion and reduce treatment response at any age, since the majority of natural GH release occurs during deep slow-wave sleep.

GHT in Older Adults: The Emerging Anti-Aging Debate

A significant coverage gap in most general-audience articles concerns the use of GHT in healthy older adults who are not clinically GH deficient but whose natural GH levels have declined with age.

GH secretion naturally declines by roughly 14% per decade after early adulthood, a process sometimes called somatopause (the age-related decline in growth hormone secretion, analogous to menopause in that it represents a predictable physiological shift rather than a disease state). By age 60, most adults secrete only 25% to 30% of the GH they produced in their 20s.

The FDA has explicitly not approved GHT for somatopause or anti-aging purposes, and prescribing it for these reasons is considered off-label use. The Federal Trade Commission (FTC) and FDA have issued joint warnings against anti-aging clinics that market GHT for healthy elderly patients without a confirmed deficiency diagnosis.

However, legitimate clinical research is ongoing. A 2019 study published in the journal Annals of Internal Medicine examined a combination of GHT, dehydroepiandrosterone (DHEA), and metformin in healthy older men and found evidence of biological age reversal in thymus tissue, a finding that generated significant scientific interest while stopping well short of demonstrating clinical benefit clear enough to change prescribing guidelines.

The National Institute on Aging, part of the U.S. National Institutes of Health, continues to fund research into GH axis modulation in aging, but current consensus among major endocrinology organizations holds that GHT for healthy adults without confirmed GHD remains investigational and carries risks including increased diabetes risk, joint swelling, carpal tunnel syndrome, and a theoretical increase in cancer risk with long-term supraphysiologic dosing.

Psychological and Quality-of-Life Dimensions Across Age Groups

The age at which GHT begins has profound psychological implications that extend well beyond centimeters gained.

Children who are significantly shorter than their peers face measurably elevated rates of bullying, social exclusion, and reduced self-esteem, effects that are well documented in pediatric psychology literature from institutions including Stanford University School of Medicine and the University of Michigan. Early GHT reduces the severity and duration of this psychosocial burden by accelerating growth into a range closer to age peers.

For adolescents starting treatment later, the psychological benefit is more complicated. A 15-year-old beginning GHT may gain only 0.5 to 1.5 inches of additional height before plates close, an outcome that can feel disappointing relative to expectations. Endocrinologists who specialize in adolescent care, including those affiliated with the Society for Adolescent Health and Medicine, emphasize setting realistic expectations through honest pre-treatment counseling.

Adult patients with GHD consistently report improvements in psychological well-being scales after 3 to 6 months of GHT. The QoL-AGHDA (Quality of Life Assessment of Growth Hormone Deficiency in Adults), a validated questionnaire used in U.S. and international clinical trials, captures domains including energy, emotional reactions, social isolation, and memory. Mean scores improve significantly within the first year of adult GHT, independent of measurable physical changes in body composition.

Injection Technology and How It Affects Age-Appropriate Delivery

The mechanics of how GHT is delivered have evolved significantly and have real implications for patients at different ages.

Traditional GHT required daily subcutaneous injections using standard insulin-style syringes. Modern delivery has shifted toward pen injection devices that are easier for parents to administer to young children and easier for teenagers to self-inject with greater accuracy and confidence.

The easypod device from Saizen is particularly notable because it electronically records each injection event and can transmit compliance data to physicians, a feature that addresses one of the most significant predictors of poor treatment outcomes across all age groups: missed doses.

A 2021 compliance study in the Journal of Clinical Endocrinology and Metabolism found that pediatric patients using electronic injection devices with reminder functions showed 23% higher adherence rates than those using standard pen devices without tracking, translating directly into meaningfully better height outcomes over a 3-year treatment period.

The once-weekly somatrogon injection approved in 2023 represents the most significant delivery advancement for pediatric compliance since pen devices replaced syringes. Clinical trials showed non-inferior height velocity (the rate of growth per year) compared to daily GHT, making it a genuine clinical alternative rather than simply a convenience option.

Conditions That Can Disqualify a Patient From GHT Regardless of Age

Not every patient with low GH levels or short stature qualifies for or can safely receive GHT. Several conditions represent absolute or relative contraindications (medical reasons to avoid a treatment) that apply regardless of age.

Absolute contraindications include:

• Active malignancy (cancer that is currently being treated or has not been in remission for a sufficient period), because GH stimulates IGF-1, which can theoretically promote tumor cell growth.
• Prader-Willi syndrome patients with severe obesity or uncontrolled respiratory problems, because GHT has been associated with sudden death in this population when these comorbidities are unmanaged.
• Diabetic retinopathy (damage to the blood vessels in the retina caused by diabetes), which GHT can worsen.
• Active intracranial hypertension (elevated pressure inside the skull) not yet under medical control.

Relative contraindications requiring careful risk-benefit discussion include:

• Personal or strong family history of certain cancers.
• Uncontrolled diabetes.
• Severe cardiomegaly (enlarged heart).
• Active autoimmune conditions under treatment.

These exclusion criteria mean that even a child presenting at the ideal treatment age with confirmed GHD may need to delay or forgo GHT until complicating conditions are adequately managed. The prescribing pediatric endocrinologist conducts a full medical history and physical examination specifically to identify these factors before initiating therapy.

FAQ’s

At what age should a child start growth hormone therapy?

Children typically begin GHT between ages 2 and 13, depending on diagnosis and remaining growth potential. Earlier initiation generally produces greater gains in final adult height because more open growth plate time remains available.

Can a 16-year-old benefit from growth hormone therapy?

Yes, a 16-year-old can still benefit from GHT if bone age testing confirms that growth plates have not yet fused. However, the height gain window is narrowing rapidly at this age, and the prescribing physician will assess bone maturity by X-ray before initiating treatment.

Is growth hormone therapy effective after age 18?

GHT after age 18 cannot increase height once growth plates have closed, but it can importantly improve body composition, bone density, cholesterol levels, and energy in adults with confirmed GHD. The FDA has approved GHT for adult GHD with no upper age cutoff.

How long does a child need to stay on growth hormone therapy?

Most children remain on GHT until their growth plates close, which typically occurs between ages 15 and 18 for females and ages 17 and 21 for males. The total duration often spans 4 to 10 years, depending on the age at diagnosis.

What is the minimum age for growth hormone therapy in the United States?

The FDA has approved GHT for children as young as age 2 for conditions including Turner syndrome, Prader-Willi syndrome, and small for gestational age. In certain clinical situations involving severe congenital GHD, treatment may begin in infancy under specialist supervision.

How much height can a child gain from growth hormone therapy?

Children with confirmed GHD who start treatment early typically gain between 1 and 4 inches in additional final adult height compared to untreated peers. Results vary based on age at diagnosis, dose, compliance, and underlying cause of deficiency.

Does growth hormone therapy work for short kids without a hormone deficiency?

The FDA approved GHT for idiopathic short stature (ISS), meaning short stature without a diagnosed cause, for children whose predicted adult height falls below 5 feet 3 inches for males and 4 feet 11 inches for females. Average height gains in ISS are more modest, typically 1 to 2 inches of additional adult height.

Can adults over 40 receive growth hormone therapy?

Adults over 40 with documented GHD confirmed by stimulation testing can receive GHT legally in the United States. Response is often more modest in older adults, and dosing is typically lower, but metabolic and quality-of-life benefits remain clinically meaningful.

How does a doctor confirm that growth hormone therapy is needed?

Diagnosis requires a GH stimulation test, where a chemical trigger is given and peak GH secretion is measured from blood draws. Children must show a peak below 10 nanograms per milliliter and adults below 3 to 5 nanograms per milliliter to confirm deficiency and qualify for treatment.

What happens if growth hormone therapy is stopped before growth plates close?

Stopping GHT prematurely before plates close results in a return to the pre-treatment growth rate, and the height gains accumulated during therapy are preserved but no additional catch-up growth occurs. Physicians recommend continuing treatment without interruption until final height is achieved for maximum benefit.

How much does growth hormone therapy cost per year for a child?

Pediatric GHT costs between $10,000 and $60,000 per year depending on the child’s weight, the specific brand prescribed, and geographic location. Most private insurance plans and Medicaid cover GHT for children with confirmed GHD, substantially reducing out-of-pocket costs for qualifying families.

Does insurance cover growth hormone therapy for children and adults?

Most U.S. private insurance plans and Medicaid cover GHT when documented GHD is confirmed through approved stimulation testing and an FDA-approved diagnosis is present. Coverage for idiopathic short stature or adult GHT for age-related decline is less consistent and often requires prior authorization and appeals.

What is the difference between pediatric and adult growth hormone therapy dosing?

Pediatric GHT doses are calculated based on body weight or body surface area, typically ranging from 0.16 to 0.24 milligrams per kilogram per week. Adult dosing starts significantly lower, often at 0.1 to 0.3 milligrams per day, and is titrated upward based on IGF-1 levels and symptom response rather than weight-based formulas.

Can growth hormone therapy be used to treat short stature caused by puberty delay?

Constitutional delay of growth and puberty (CDGP), meaning naturally late puberty with no hormone deficiency, does not typically qualify for GHT under FDA-approved indications. Physicians may monitor these patients closely and reassess if growth remains severely below expected norms after puberty resolves.

Are there risks specific to starting growth hormone therapy at a young age?

Starting GHT at a young age is generally considered safe when medically supervised, but potential risks include increased intracranial pressure, slipped capital femoral epiphysis (a hip joint problem), fluid retention, and long-term monitoring requirements for cancer risk in those with predisposing conditions. Regular follow-up with a pediatric endocrinologist reduces these risks substantially.

What is somatopause and can it be treated with growth hormone therapy?

Somatopause is the natural age-related decline in growth hormone secretion, estimated at roughly 14% per decade after early adulthood. The FDA has not approved GHT for somatopause in otherwise healthy adults, and major endocrinology organizations consider its use for this purpose investigational and potentially risky without a confirmed deficiency diagnosis.

Is once-weekly growth hormone therapy available and does it work as well as daily injections?

Yes, somatrogon (brand name Ngenla) received FDA approval in 2023 as a once-weekly GHT option for pediatric patients. Clinical trials demonstrated non-inferior height velocity compared to daily GHT, meaning growth rates were statistically equivalent, making it a clinically valid alternative that significantly reduces the injection burden for children and families.

Can Laron syndrome be treated with standard growth hormone therapy?

No. Laron syndrome is caused by a defect in the GH receptor gene that prevents the body from responding to growth hormone, meaning standard GHT produces no benefit regardless of dose or age. These patients are instead treated with mecasermin (recombinant IGF-1, sold as Increlex), which bypasses the broken GH receptor and directly delivers the downstream growth signal.

How does obesity affect growth hormone therapy diagnosis and dosing?

Obesity significantly suppresses GH secretion during stimulation testing, which can produce falsely low peak GH values that mimic GHD in people who are not actually deficient. Endocrinologists use BMI-adjusted diagnostic cutoffs to account for this effect, and adult GHT dosing in obese patients is typically started at lower levels and titrated more cautiously to avoid side effects like fluid retention and insulin resistance.

What support organizations exist for families navigating growth hormone therapy in the United States?

The Human Growth Foundation is a leading nonprofit organization that provides education, advocacy, and financial assistance resources for patients with growth disorders across the United States. The MAGIC Foundation (Major Aspects of Growth in Children) similarly offers support for children and families dealing with GHD, Turner syndrome, and related conditions, including a national network of parent support groups and a physician referral directory.

What is the difference between childhood-onset and adult-onset growth hormone deficiency?

Childhood-onset GHD occurs when the pituitary gland fails to produce adequate growth hormone from an early age, often due to congenital abnormalities, and may persist into adulthood requiring re-testing at transition. Adult-onset GHD develops later in life, most commonly from pituitary adenomas, brain surgery, radiation therapy, or traumatic brain injury, and is diagnosed using stimulation tests with stricter cutoff thresholds than those used in pediatric practice.